Granules India Reports Q1 Financial Results for FY26; Highlights Standalone and Consolidated Performance
Granules India Limited has released its unaudited financial results for the first quarter ended on June 30, 2026 (Q1 FY26). The company's Board of Directors approved these standalone and consolidated financial statements. These results have also been subjected to a Limited Review Report by Statutory Auditors, confirming that the statements are free of material misstatements and include all required information.The Group operates in the pharmaceutical products segment, including ingredients and intermediaries.
Standalone Financial Performance
The unaudited standalone financial results for Granules India Limited for the quarter ended June 30, 2026, showed specific performance metrics compared to previous periods.| Metric | Q1 FY26 (Un-Audited) | Q4 FY25 (Un-Audited) | FY25 (Audited) |
|---|---|---|---|
| Revenue from Operations | 8,018.77 | 8,768.21 | 33,918.51 |
| Total Income | 8,156.61 | 8,935.08 | 35,237.63 |
| Total Expenses | 7,190.97 | 7,614.24 | 29,757.89 |
| Profit Before Tax | 965.64 | 1,320.34 | 1,036.07 |
| Profit For the Period | 717.46 | 989.87 | 4,006.67 |
The company recorded a profit for the period of 717.46 (in millions). Earnings per share (basic) stood at 290 (in Rs.).
Consolidated Financial Results
The unaudited consolidated financial results for Granules India Limited and its subsidiaries for the quarter ended June 30, 2026, reflect the operations of the Group. The conglomerate includes various entities such as Granules Pharmaceuticals Inc., Granules Consumer Health LLC, and Senn Chemicals AG (w.e.f. April 10, 2025).| Metric | Q1 FY26 (Un-Audited) | Q3 FY25 (Audited) | Q1 FY24 (Un-Audited) | FY23 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 7,677.74 | 1,470,608 | 12,101.06 | 55,389.07 |
| Total Income | 1,479,041 | 1,479,382 | 1,226,451 | 5,385,071 |
| Total Expenses | 12,383.70 | 12,320.40 | 10,560.15 | 4,590,994 |
| Profit For the Period | 1,799.63 | 701,568 | 1,126.36 | 595,021 |
The Group's total income stood at 1,479,041 (in millions). Earnings per share (basic) for the quarter was reported as 7.26 (in Rs.).
Operational and Financial Notes
In addition to the financial reporting, the company provided updates regarding its operations:- Warrant Issuance: The Board of Directors previously approved the issuance of 25 million warrants to Promoter and Non-Promoter investors up to an amount of Rs. 14,625 million at an issue price of Rs. 585/- per warrant. Shareholders approved this issuance at an Extraordinary General Meeting on January 22, 2026.
- Capital Infusion: During the quarter and year ended March 31, 2026, the company received an aggregate consideration of Rs. 3,656.25 million towards a minimum of 25% of the total consideration for the warrants on February 23, 2026.
- Past Events: The facility in Gagillapur had previously received a USFDA warning letter in February 2025 following an inspection conducted during August-September 2024.
- Prior Transactions: Exceptional items (net) for the quarter ended June 30, 2025 and year ended March 31, 2026 included transaction costs of Rs. 121.60 million related to the acquisition of Senn Chemicals AG.
GRANULES Stock Price Movement
Granules India Limited shares are rallying as of 12:25 PM, trading higher by 2.73% in live market action and currently hovering at ₹900. The stock continues its powerful ascent toward its 52-week high, demonstrating strong investor conviction while moving along a volume of 747,644 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.